IL254772A0 - Pharmaceutical preparations for combination therapy - Google Patents

Pharmaceutical preparations for combination therapy

Info

Publication number
IL254772A0
IL254772A0 IL254772A IL25477217A IL254772A0 IL 254772 A0 IL254772 A0 IL 254772A0 IL 254772 A IL254772 A IL 254772A IL 25477217 A IL25477217 A IL 25477217A IL 254772 A0 IL254772 A0 IL 254772A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
combination therapy
therapy
combination
pharmaceutical
Prior art date
Application number
IL254772A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of IL254772A0 publication Critical patent/IL254772A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL254772A 2015-04-07 2017-09-28 Pharmaceutical preparations for combination therapy IL254772A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07
PCT/US2016/026146 WO2016164413A1 (en) 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
IL254772A0 true IL254772A0 (en) 2017-12-31

Family

ID=57072872

Family Applications (2)

Application Number Title Priority Date Filing Date
IL254772A IL254772A0 (en) 2015-04-07 2017-09-28 Pharmaceutical preparations for combination therapy
IL268316A IL268316B (en) 2015-04-07 2019-07-29 Pharmaceutical preparations for combined treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL268316A IL268316B (en) 2015-04-07 2019-07-29 Pharmaceutical preparations for combined treatment

Country Status (25)

Country Link
US (1) US10894054B2 (enExample)
EP (1) EP3280421B1 (enExample)
JP (1) JP6879931B2 (enExample)
KR (1) KR20170132879A (enExample)
CN (1) CN107613986A (enExample)
AR (1) AR104195A1 (enExample)
AU (1) AU2016246524B2 (enExample)
BR (1) BR112017021311A2 (enExample)
CA (1) CA2981507A1 (enExample)
CL (2) CL2017002538A1 (enExample)
CO (1) CO2017010292A2 (enExample)
CR (1) CR20170456A (enExample)
EA (1) EA036757B1 (enExample)
EC (1) ECSP17073004A (enExample)
ES (1) ES2974281T3 (enExample)
IL (2) IL254772A0 (enExample)
MA (1) MA41083A1 (enExample)
MX (1) MX2017012893A (enExample)
NI (1) NI201700121A (enExample)
PE (1) PE20180034A1 (enExample)
SM (1) SMT202400104T1 (enExample)
SV (1) SV2017005539A (enExample)
TN (1) TN2017000426A1 (enExample)
TW (1) TW201642869A (enExample)
WO (1) WO2016164413A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
JP2019519478A (ja) 2016-04-19 2019-07-11 ユレカ・ソシエテ・ア・レスポンサビリテ・リミテＵｒｅｋａ Ｓａｒｌ ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
US12569543B2 (en) 2016-04-28 2026-03-10 Novo Nordisk A/S Semaglutide in cardiovascular conditions
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
SG11201903697WA (en) * 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
KR20210002573A (ko) * 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
US20210393662A1 (en) * 2018-10-18 2021-12-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3886892A1 (en) * 2018-11-30 2021-10-06 UREKA Sarl Peptide-oligourea foldamer compounds and methods of their use
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
EP3946359A1 (en) * 2019-03-26 2022-02-09 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020205024A1 (en) * 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
US20240100125A1 (en) * 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022152773A1 (en) * 2021-01-14 2022-07-21 Enyo Pharma Method for treating chronic kidney diseases
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2023284453A1 (en) * 2022-06-08 2024-12-19 Kojin Therapeutics, Inc. Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof
CN120789063B (zh) * 2025-08-15 2026-02-10 北京大学第三医院（北京大学第三临床医学院） 一种药物组合物、制剂及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CZ301366B6 (cs) * 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
AU2004261660A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
RS20060320A (sr) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
LT2347762T (lt) * 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
WO2007076260A2 (en) * 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2007095174A2 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
AU2007267692B2 (en) 2006-05-24 2012-06-14 Eli Lilly And Company Compounds and methods for modulating FXR
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
CN101522703B (zh) 2006-06-27 2013-04-17 英特塞普特医药品公司 胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20100056546A1 (en) 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
EP2435033A1 (en) 2009-05-27 2012-04-04 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6258586B2 (ja) * 2010-02-24 2018-01-10 レリプサ， インコーポレイテッド 胆汁酸捕捉剤として使用するためのアミンポリマー
WO2011150285A1 (en) 2010-05-26 2011-12-01 Adm Tronics Unlimited Inc. Apparatus and method for uroflowmetry
EP3593802A3 (en) * 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
KR20130101057A (ko) 2010-09-15 2013-09-12 스미토모 덴키 고교 가부시키가이샤 레이저 가공 방법
WO2012106581A1 (en) 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
TN2017000344A1 (en) * 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
JP2018510900A (ja) 2018-04-19
CL2018001007A1 (es) 2018-06-15
ES2974281T3 (es) 2024-06-26
AR104195A1 (es) 2017-07-05
CA2981507A1 (en) 2016-10-13
EP3280421A4 (en) 2019-08-28
IL268316B (en) 2022-02-01
CL2017002538A1 (es) 2018-04-20
IL268316A (en) 2019-09-26
PE20180034A1 (es) 2018-01-09
TN2017000426A1 (en) 2019-04-12
US20180117065A1 (en) 2018-05-03
MX2017012893A (es) 2018-01-15
TW201642869A (zh) 2016-12-16
CO2017010292A2 (es) 2018-01-05
WO2016164413A1 (en) 2016-10-13
CN107613986A (zh) 2018-01-19
SMT202400104T1 (it) 2024-05-14
ECSP17073004A (es) 2018-02-28
KR20170132879A (ko) 2017-12-04
US10894054B2 (en) 2021-01-19
JP6879931B2 (ja) 2021-06-02
AU2016246524A1 (en) 2017-10-26
NI201700121A (es) 2018-01-10
EA036757B1 (ru) 2020-12-17
MA41083A1 (fr) 2018-05-31
EA201792203A1 (ru) 2018-02-28
EP3280421B1 (en) 2023-12-27
SV2017005539A (es) 2019-01-18
EP3280421A1 (en) 2018-02-14
CR20170456A (es) 2018-06-13
BR112017021311A2 (pt) 2018-06-26
AU2016246524B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
IL268316B (en) Pharmaceutical preparations for combined treatment
ZA201906613B (en) Pharmaceutical compositions for combination therapy
ZA201706007B (en) Pharmaceutical compositions for combination therapy
ZA201905510B (en) Pharmaceutical compositions for combination therapy
GB201504675D0 (en) Pharmaceutical compounds
PL4233846T3 (pl) Formulacje farmaceutyczne
GB201608323D0 (en) Pharmaceutical compositions
IL256491A (en) Pharmaceutical formulations
GB201521462D0 (en) Pharmaceutical composition
GB201506526D0 (en) Medicinal composition
ZA201707094B (en) Pharmaceutical formulations
IL255510A (en) Pharmaceutical compositions
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
ZA201500995B (en) Low dose pharmaceutical composition
ZA201705782B (en) Pharmaceutical compositions
GB201520762D0 (en) Novel pharmaceutical compositions
ZA201705783B (en) Pharmaceutical compositions
PT3319596T (pt) Composições farmacêuticas
GB201700831D0 (en) Pharmaceutical compositions
GB201521456D0 (en) Pharmaceutical composition